

Press release

Amoéba: Publication of the half-year financial report as of June 30, 2025

Chassieu (France), October 24, 2025 – 6:00 p.m - Amoéba (FR0011051598 - ALMIB), industrial greentech specialized in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has made available and filed with the French Financial Markets Authority (AMF) its half-year financial report as of June 30, 2025.

The half-year financial report as of June 30, 2025, can be consulted on the company's website at the following address: <https://amoeba-nature.com/> in the section "Investor" / "Financial Documents" / "2025" / "Half-year financial Report".

About Amoéba:

Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the treatment of microbiological risk based on the patented use of amoebae in the plant protection and cosmetics sectors.

With know-how that is unique in the world and protected by numerous patents, Amoéba is currently the only company capable of exploiting the full potential of the *Willaeertia* amoeba on an industrial scale and cultivating it in sufficient volumes to offer biological solutions that constitute a viable alternative to the chemical products widely used today. Amoéba is currently focusing on the global biocontrol market for plant protection and on the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory authorisations, the Company has obtained marketing authorisation in the United States and the necessary regulatory procedures are underway in several European countries. The active substance has obtained approval in 2022 in the USA and in 2025 in Europe. Product approvals have been granted in the USA and are expected in the coming months in Europe.

The cosmetic application does not require prior approval from a competent authority in Europe or the United States. The cosmetic ingredient is already registered on the INCI (International Nomenclature of Cosmetic Ingredients) list, paving the way for it to be marketed worldwide except in China, where local approval is required.

Amoéba is listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme. For more information, visit www.amoeba-nature.com.

Contacts:

Amoéba

Chief Executive Officer

Jean-François DOUCET

☎ +33 (0)4 26 69 16 00

✉ [jf.doucet@amoeba-](mailto:jf.doucet@amoeba-nature.com)

nature.com

ACTUS finance & communication

Investor relations

Pierre JACQUEMIN-

GUILLAUME

☎ +33 (0)1 53 67 36 79

✉ amoeba@actus.fr

Financial press relations

Serena BONI

☎ +33 (0)4 72 18 04 92

✉ sboni@actus.fr

Droit Devant Agency

Business and general public press relations

Laëtitia PINTO

☎ +33 (0)7 64 83 39 85

✉ pinto@droitdevant.fr

Disclaimer

This press release contains certain forward-looking statements concerning Amoéba which are based on its own assumptions and estimates and on information that is currently available to us. However, Amoéba gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in Amoéba's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 17, 2025 under number D.25-0281 and available on the Amoéba website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to Amoéba or not currently considered material by Amoéba. The occurrence of all or part of such risks could cause Amoéba's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.